Literature DB >> 8984919

Exhaled nitric oxide in paediatric asthma and cystic fibrosis.

J O Lundberg1, S L Nordvall, E Weitzberg, H Kollberg, K Alving.   

Abstract

Nitric oxide (NO) is present in exhaled air of humans. This NO is mostly produced in the upper airways, whereas basal NO excretion in the lower airways is low. Children with Kartagener's syndrome have an almost total lack of NO in nasally derived air, whereas adult asthmatics have increased NO in orally exhaled air. NO excretion was measured in the nasal cavity and in orally exhaled air in 19 healthy children, in 36 age matched subjects with asthma, and in eight children with cystic fibrosis. NO levels in orally exhaled air were similar in controls and in children with cystic fibrosis, at 4.8 (SD 1.2) v 5.8 (0.8) parts per billion (ppb), but were increased in asthmatic children who were untreated or were being treated only with low doses of inhaled steroids (13.8 (2.5) ppb). Nasal NO levels were reduced by about 70% in children with cystic fibrosis compared to controls and asthmatics. Measurements of airway NO release in different parts of the airways may be useful in non-invasive diagnosis and monitoring of inflammatory airway diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8984919      PMCID: PMC1511735          DOI: 10.1136/adc.75.4.323

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  16 in total

1.  Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans.

Authors:  L E Gustafsson; A M Leone; M G Persson; N P Wiklund; S Moncada
Journal:  Biochem Biophys Res Commun       Date:  1991-12-16       Impact factor: 3.575

2.  Modulation of airway epithelial cell ciliary beat frequency by nitric oxide.

Authors:  B Jain; I Rubinstein; R A Robbins; K L Leise; J H Sisson
Journal:  Biochem Biophys Res Commun       Date:  1993-02-26       Impact factor: 3.575

3.  Autoinhalation of nitric oxide after endogenous synthesis in nasopharynx.

Authors:  H Gerlach; R Rossaint; D Pappert; M Knorr; K J Falke
Journal:  Lancet       Date:  1994-02-26       Impact factor: 79.321

4.  Single-breath nitric oxide measurements in asthmatic patients and smokers.

Authors:  M G Persson; O Zetterström; V Agrenius; E Ihre; L E Gustafsson
Journal:  Lancet       Date:  1994-01-15       Impact factor: 79.321

5.  Induction of nitric oxide synthase in asthma.

Authors:  Q Hamid; D R Springall; V Riveros-Moreno; P Chanez; P Howarth; A Redington; J Bousquet; P Godard; S Holgate; J M Polak
Journal:  Lancet       Date:  1993 Dec 18-25       Impact factor: 79.321

6.  Evidence for antiviral effect of nitric oxide. Inhibition of herpes simplex virus type 1 replication.

Authors:  K D Croen
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

7.  Increased amount of nitric oxide in exhaled air of asthmatics.

Authors:  K Alving; E Weitzberg; J M Lundberg
Journal:  Eur Respir J       Date:  1993-10       Impact factor: 16.671

8.  High nitric oxide production in human paranasal sinuses.

Authors:  J O Lundberg; T Farkas-Szallasi; E Weitzberg; J Rinder; J Lidholm; A Anggåard; T Hökfelt; J M Lundberg; K Alving
Journal:  Nat Med       Date:  1995-04       Impact factor: 53.440

9.  Effects of nitric oxide and nitrogen dioxide on bacterial growth.

Authors:  R L Mancinelli; C P McKay
Journal:  Appl Environ Microbiol       Date:  1983-07       Impact factor: 4.792

10.  Increased nitric oxide in exhaled air of asthmatic patients.

Authors:  S A Kharitonov; D Yates; R A Robbins; R Logan-Sinclair; E A Shinebourne; P J Barnes
Journal:  Lancet       Date:  1994-01-15       Impact factor: 79.321

View more
  28 in total

Review 1.  Nasal nitric oxide in man.

Authors:  J O Lundberg; E Weitzberg
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

2.  Dissociation between exhaled nitric oxide and hyperresponsiveness in children with mild intermittent asthma.

Authors:  M Silvestri; D Spallarossa; E Battistini; V Brusasco; G A Rossi
Journal:  Thorax       Date:  2000-06       Impact factor: 9.139

Review 3.  "CF asthma": what is it and what do we do about it?

Authors:  I M Balfour-Lynn; J S Elborn
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

4.  Exhalation flow and pressure-controlled reservoir collection of exhaled nitric oxide for remote and delayed analysis.

Authors:  P Paredi; S Loukides; S Ward; D Cramer; M Spicer; S A Kharitonov; P J Barnes
Journal:  Thorax       Date:  1998-09       Impact factor: 9.139

5.  Exhaled breath condensate pH and exhaled nitric oxide in allergic asthma and in cystic fibrosis.

Authors:  J C Ojoo; S A Mulrennan; J A Kastelik; A H Morice; A E Redington
Journal:  Thorax       Date:  2005-01       Impact factor: 9.139

6.  An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications.

Authors:  Raed A Dweik; Peter B Boggs; Serpil C Erzurum; Charles G Irvin; Margaret W Leigh; Jon O Lundberg; Anna-Carin Olin; Alan L Plummer; D Robin Taylor
Journal:  Am J Respir Crit Care Med       Date:  2011-09-01       Impact factor: 21.405

7.  Exhaled nitric oxide is reduced in infants with cystic fibrosis.

Authors:  H E Elphick; E A Demoncheaux; S Ritson; T W Higenbottam; M L Everard
Journal:  Thorax       Date:  2001-02       Impact factor: 9.139

Review 8.  Phenotypes of Chronic Rhinosinusitis.

Authors:  Seong H Cho; Daniel L Hamilos; Doo Hee Han; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol Pract       Date:  2020-05

9.  Origin of nitrite and nitrate in nasal and exhaled breath condensate and relation to nitric oxide formation.

Authors:  H Marteus; D C Törnberg; E Weitzberg; U Schedin; K Alving
Journal:  Thorax       Date:  2005-03       Impact factor: 9.139

10.  Myeloperoxidase-dependent oxidative metabolism of nitric oxide in the cystic fibrosis airway.

Authors:  Anna L P Chapman; Brian M Morrissey; Vihas T Vasu; Maya M Juarez; Jessica S Houghton; Chin-Shang Li; Carroll E Cross; Jason P Eiserich
Journal:  J Cyst Fibros       Date:  2010-01-15       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.